Antibody combo for newly diagnosed follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two antibody medications, tafasitamab and rituximab, as the first treatment for newly diagnosed follicular lymphoma. The goal is to see if this combination can effectively control the lymphoma and potentially reduce the need for more intensive therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a new diagnosis of follicular lymphoma (a slow-growing type of lymphoma).
- Your lymphoma must be causing symptoms or growing enough that treatment is needed.
- You must have at least one enlarged lymph node or other measurable sign of lymphoma.
- You must be in reasonably good health (able to do daily activities, with adequate organ function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medications (acalabrutinib, lenalidomide, and rituximab) for people with a type of slow-growing lymphoma called follicular lymphoma. The goal is to see if this combination can control the disease and possibly lead to remission.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, and venetoclax) for people with untreated follicular lymphoma. The goal is to see if this combination works better than standard treatments and has manageable side effects.
This trial tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) for people newly diagnosed with follicular lymphoma. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of three drugs (tafasitamab, lenalidomide, and rituximab) for people with newly diagnosed follicular or marginal zone lymphoma who have not had treatment before. The goal is to see if this combination works well and is safe.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
This study tests a new drug combination (using two targeted medicines and an immunotherapy drug) versus a standard chemotherapy combination for people with untreated follicular lymphoma. The goal is to see if the new combo works better with fewer side effects.
Hear when a new Grade 1 Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.